Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics VKTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 40% bearish. Among these notable options, 4 are puts, totaling $243,720, and 6 are calls, amounting to $226,072.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $50.0 for Viking Therapeutics over the last 3 months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Viking Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Viking Therapeutics's substantial trades, within a strike price spectrum from $30.0 to $50.0 over the preceding 30 days.
Viking Therapeutics Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | PUT | SWEEP | BULLISH | 02/21/25 | $10.5 | $10.3 | $10.4 | $50.00 | $126.8K | 1.0K | 184 |
| VKTX | CALL | SWEEP | BEARISH | 05/16/25 | $7.7 | $7.3 | $7.37 | $50.00 | $65.8K | 2.0K | 97 |
| VKTX | PUT | SWEEP | BULLISH | 01/17/25 | $4.2 | $4.1 | $4.1 | $44.50 | $46.7K | 3 | 117 |
| VKTX | PUT | SWEEP | BULLISH | 02/21/25 | $10.6 | $10.4 | $10.4 | $50.00 | $41.6K | 1.0K | 62 |
| VKTX | CALL | TRADE | BULLISH | 02/21/25 | $3.8 | $3.6 | $3.76 | $50.00 | $37.6K | 3.8K | 402 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Having examined the options trading patterns of Viking Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of Viking Therapeutics
- With a trading volume of 694,938, the price of VKTX is down by -0.83%, reaching $42.0.
- Current RSI values indicate that the stock is may be approaching oversold.
- Next earnings report is scheduled for 41 days from now.
What Analysts Are Saying About Viking Therapeutics
In the last month, 4 experts released ratings on this stock with an average target price of $95.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $102. * In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $74. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $102. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $102.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Viking Therapeutics with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
